Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $42.3 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2022 revenue of $185-195 million, versus the consensus of $187.6 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.